OMICS International

International Conferences

Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series Ltd: World’s leading Event Organizer

 

Recommended Conferences for Pharmaceutical Industry

Pharmaceutical Industry


As per available reports about10 relevant journals, 71 Conferences, 6 workshops are presently dedicated exclusively to Pharmaceutical Industry and about 1543 articles are being published on Pharmaceutical Industry.

The pharmaceutical industry advances, produces, and markets drugs or pharmaceuticals approved for use as medications. Pharmaceutical companies are acceptable to deal in generics or brand medications and medical devices. They are subject to a variety of laws and regulations about the patenting, testing and confirming safety and efficiency and marketing of drugs. Most of today's major pharmaceutical companies were founded in the late 19th and early 20th centuries. Key discoveries of the 1920s and 1930s, such as insulin and penicillin, became mass-manufactured and distributed. Switzerland, Germany and Italy had particularly strong industries, with the United Kingdom, the United States, Belgium and the Netherlands following suit. Pharmaceutical Legislation was enacted to test and approve drugs and to require appropriate labelling.

OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.

Scope and Importance

Prescription and non-prescription drugs became legally distinguished from one another as the pharmaceutical industry matured. The industry got underway in earnest from the 1950s, due to the development of systematic scientific approaches, understanding of human biology and sophisticated manufacturing techniques. Drug discovery is the process by which potential drugs are discovered or designed. In the past most drugs have been discovered either by isolating the active ingredient from traditional remedies or by serendipitous discovery. Modern biotechnology often focuses on understanding the metabolic pathways related to a disease state or pathogen, and manipulating these pathways using molecular biology or biochemistry. A great deal of early-stage drug discovery has traditionally been carried out by universities and research institutions. Drug development refers to activities undertaken after a compound is identified as a potential drug in order to establish its suitability as a medication. Objectives of drug development are to determine appropriate formulation and dosing, as well as to establish safety. Research in these areas generally includes a combination of in vitro studies, in vivo studies, and clinical trials. The amount of capital required for late stage development has made it a historical strength of the larger pharmaceutical companies. Large multinational corporations exhibit vertical integration, participating in a broad range of drug discovery and development, manufacturing and quality control, marketing, sales, and distribution. Smaller organizations, on the other hand, often focus on a specific aspect such as discovering drug candidates or developing formulations. Often, collaborative agreements between research organizations and large pharmaceutical companies are formed to explore the potential of new drug substances. More recently, multi-nationals are increasingly relying on contract research organizations to manage drug development. Drug companies are like other companies in that they manufacture products that must be sold for a profit in order for the company to survive and grow. They are different from some companies because the drug business is very risky. For instance, only one out of every ten thousand discovered compounds actually becomes an approved drug for sale. Much expense is incurred in the early phases of development of compounds that will not become approved drugs. In addition, it takes about 7 to 10 years and only 3 out of every 20 approved drugs bring in sufficient revenue to cover their developmental costs, and only 1 out of every 3 approved drugs generates enough money to cover the development costs of previous failures. This means that for a drug company to survive, it needs to discover a blockbuster (billion-dollar drug) every few years. In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational New Drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include Pharmacokinetics and Dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA reviews the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted. Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's 'golden era' in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues.

Market Analysis

The market was valued at US$1.56 billion in 2013 and is estimated to reach a value of US$4.49 billion by the end of 2020.With the help of regulatory affairs outsourcing, life science, pharmaceutical, and medical device manufacturing companies are able to get their drugs or devices approved or launched in the global market. Regulatory affairs outsourcing by biopharmaceutical companies has minimized losses due to recalls and product approval delays. Regulatory affairs service providers also provide effective services such as clinical trial services, medical writing, and pharmacovigilance to biotech, pharma, and medical device companies.
 

International symposium and workshops

  • VIth Asia pacific pharma congress on July 14-16, 2016 , Kuala lumpur, Malaysia
  • VIIth   Annual global Pharma Summit June 20-22, 2016 New Orleans, USA
  • Vth  Global Pharmacists Annual Meeting July 11-13, 2016 Brisbane, Australia

          List of Best International Conferences

  • 6th Pharmaceutical Regulatory Affairs and IPR Conference September 12-14, 2016 San Atonio, USA
  • 7th Analytical and Bioanalytical Techniques Conference, September 29-October 01, 2016 Miami, USA
  • Pharma Conference, August 25-27, 2015 Valencia, Spain
  • 8th Pharmaceutics and Novel Drug Delivery Systems Conference, March 07-09, 2016 Madrid, Spain
  • Drug Formulation and Bioavailability Conference June 06-08, 2016 Beijing, China
  • Pharma Marketing Conference November 17-19, 2016 Alicante, Spain
  • 6th Pharmacovigilance Conference Canada August 01-03, 2016 Toronto, Canada
  • 4th  GMP, GCP and Quality Control Conference October 26-28, 2015 Hyderabad, India
  • Pharma Conference Middle East November 02-04, 2015 Dubai, UAE
  • Industrial Pharmacy Conference April 11-12, 2016 Dubai, UAE
  • 3rd Annual International Conference on Pharmacology and Pharmaceutical Sciences (PHARMA) 26-27 October 2015, Bangkok Thailand
  •  Pharma Africa Market Access Conference 24 - 25 September 2015 London, UK
  •  International Conference and Expo on Bio pharmaceutics September 21-22, 2015 Baltimore, MD, USA

    Relevant Companies
     
    •Abbott Laboratories
    •Ego Pharmaceuticals
    •Eli Lilly and Company
    •General Pharma
    •Getz Pharma
    •GlaxoSmithKline
    •Glenmark Pharmaceuticals
    •Pharmacosmos
    •Avella Specialty Pharmacy
    •Axcan Pharma
    •Aurobindo Pharma
    •Daiichi Sankyo
    •Dainippon Sumitomo Pharma
    •Dawakhana Shifaul Amraz
    •Debiopharm
    •Diabetology Ltd
    •Diffusion Pharmaceuticals
    •Dr. Reddy's Laboratories
     
    Relevant Associations
     
    •Regulations & Guidelines - Indian Pharmaceutical Association
    •Drugs Control - Indian Pharmacist Association
    •Central Drugs Standard Control Organization
    •Indian Drug Manufacturers' Association
    •DIA- Drug Information Association
    •The California Naturopathic Doctors Association
    •Texas Pharmacy Today - Texas Pharmacy Association
    •International Harm Reduction Association
    •American Pharmacists Association (APhA)
    •American Society for Pharmacy Law
    •American Society of Consultant Pharmacists Foundation
    •American Society of Consultant Pharmacists (ASCP)
    •American Society of Health-System Pharmacists (ASHP)
    •National Community Pharmacists Association (NCPA)
    •International Pharmaceutical Federation (FIP)
    •European Pharmaceutical Union (EPU)
    •Pharmaceutical Group of the European Union (PGEU)
    •European Association of Employed Community Pharmacists in Europe (EPhEU)
    •Pharmaceutical Society of Australia
    •The Brazilian Association of Regulatory Agencies
    •Insurance Regulatory Committee
    •Compliance & Regulation(IBABC)
    •EAP: Regulations
    •Amusement Ride Safety Regulations and Standards (IAAPA)
    •Commonwealth Pharmacists Association (CPA)
     

This page will be updated regularly.

This page was last updated on 14th Sep, 2015

Conferenceseries Destinations

Contact Us

Medical Conferences
Jessie Grace
jessie.grace@conferenceseries.com
1-702-508-5200 Ext:8031, 8041

Pharmaceutical Conferences
Badoni Victor
badoni.victor@conferenceseries.com
1-702-508-5200 Ext:8045, 8047

Immunology & Microbiology Conferences
Walker Smith
walker.smith@conferenceseries.com
1-702-508-5200 Ext:8031

Cancer Conferences
Raul Cliff
raul.cliff@conferenceseries.com
1-702-508-5200 Ext:8039

Nursing and Healthcare Conferences
Jennifer Leny
jennifer.leny@conferenceseries.com
1-702-508-5200 Ext:8044

Diabetes Conferences
Stanley knight
stanley.knight@conferenceseries.com
1-702-508-5200 Ext:8040

Neuroscience Conferences
Sandeep Kumar
sandeep@conferenceseries.com
1-702-508-5200 Ext:8034

Dental Conferences
Raul Cliff
raul.cliff@conferenceseries.com
1-702-508-5200 Ext:8039

Clinical and Biochemistry Conferences
Rohit Casper
rohit.casper@conferenceseries.com
1-702-508-5200 Ext:8033

Biotechnology Conferences
Ravi Vittal
ravi.vittal@conferenceseries.com
1-702-508-5200 Ext:8031, 8037

Material Science Conferences
Lucy Grey
lucygrey@conferenceseries.com
1-702-508-5200 Ext:8035

Genetics & Mol Biology Conferences
Stephen Bruce
stephen.bruce@conferenceseries.com
1-702-508-5200 Ext:8038

Engineering Conferences
Dolly A
dolly@conferenceseries.com
+1-702-508-5200 Ext:8051

Program Enquiries
Symposia/Workshops
Sponsorships
Media Partners | Advertising